Dr. Greg Verdine is a leader in the discovery, development and commercialization of new drug modalities. A passionate and accomplished inventor of novel approaches and drug classes to engage targets widely believed intractable, Dr. Verdine coined the phrase “drugging the undruggable” to describe his life’s mission. FogPharma was born from the new modality scientific work of Dr. Verdine. Together with co-founder WeiQing Zhou, he developed the scientific and business concept for the company and co-led its capitalization and operationalization in mid-2016. Dr. Verdine is highly regarded for having moved seamlessly between roles as an academic scientist, biotech entrepreneur, investor, and company executive. As Erving Professor at Harvard University and Harvard Medical School, he invented stapled peptides, including the precursor to the Phase II molecule ALRN 6924, and also made seminal contributions to understanding fundamental mechanisms of DNA repair and epigenetic DNA methylation. As an entrepreneur, Dr. Verdine has founded multiple, public biotech companies including Variagenics, Enanta, Eleven Bio, Tokai, Wave Life Sciences, and Aileron, and a private company, Gloucester Pharmaceuticals, that was acquired by Celgene. These companies have succeeded in achieving FDA approval for three marketed drugs. Dr. Verdine has served on the board of directors of Enanta Pharmaceuticals, Wave Life Sciences, Warp Drive Bio, and LifeMine Therapeutics. Having led the formation and financing of Wave Life Sciences, Warp Drive Bio and LifeMine, Dr. Verdine took a role in managing these companies as their president, chief executive officer and chief scientific officer. Dr. Verdine earned his Ph.D. in chemistry from Columbia University and served as an NIH postdoctoral fellow in molecular biology at MIT and Harvard Medical School.